Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  mitoxantrone hydrochloride
Find trials that include:  Any drugs shown
Results 1-25 of 27 for your search:
Start Over
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981
Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1331, NCI-2014-00631, COG-AALL1331, NCT02101853
Tretinoin and Arsenic Trioxide in Treating Patients with Untreated Acute Promyelocytic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: AAML1331, NCI-2014-02266, PAAML1331_A01PAMDREVW0, NCT02339740
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2215-CL-0301, NCI-2015-00931, 2015-000140-42, NCT02421939
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients with Down Syndrome
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 91 days to 3 years
Trial IDs: AAML1531, NCI-2015-00324, NCT02521493
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: 2652.00, NCI-2012-02224, 2652, FH#2652, NCT01729845
Study of Carfilzomib in Combination With Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and under
Trial IDs: CFZ008, NCI-2014-02601, 2014-001633-84, NCT02303821
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GMI-1271-201, NCI-2015-01237, NCT02306291
Risk-Directed Therapy in Treating Young Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: ALLR18, NCI-2012-00587, NCT01700946
Microtransplantation in Treating Younger Patients with Refractory or Relapsed Hematological Malignancies
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: MITREL, NCI-2015-00691, NCT02433483
CIP-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CCCWFU 22215, NCI-2015-01002, IRB00033779, NCT02484391
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients with High-Risk Acute Myeloid Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15D.377, NCI-2015-01507, 2013-087, CCRRC 2013-087, JT#5530, JT#5530/CCRRC 2013-087, NCT02583893
Bortezomib, Vorinostat, and Combination Chemotherapy in Treating Infants with Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 and under
Trial IDs: TINI, NCI-2015-01493, NCT02553460
Alvocidib Biomarker-driven Phase 2 AML Study
Phase: Phase II
Type: Treatment
Age: 18 to 65
Trial IDs: TPI-ALV-201, NCI-2015-02082, NCT02520011
Lenalidomide, Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myelogenous Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 12-202, NCI-2012-01927, NCT01681537
Brentuximab Vedotin, Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-040, NCI-2013-01114, NCT01830777
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients with High-Risk Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0111, NCI-2012-02028, 12-0111-AM002, 12-0111-CR003, NCT01839240
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HEMAML0024, NCI-2013-01349, 27313, NCT01904643
Ixazomib Citrate, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: CASE7913, NCI-2014-00371, MLN9708, X16014, X16014_MLN9708, NCT02070458
Selinexor and Chemotherapy in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 14089, NCI-2014-02229, NCT02299518
Selinexor with Combination Chemotherapy in Treating Patients with Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: IRB15-0412, NCI-2015-01647, NCT02573363
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AG120-221-C-001, NCI-2015-02291, NCT02632708
Start Over